<?xml version="1.0" encoding="UTF-8"?>
<ref id="B80-pathogens-09-00231">
 <label>80.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Sebastian</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Schr√∂der</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Scheel</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Hong</surname>
    <given-names>H.S.</given-names>
   </name>
   <name>
    <surname>Muth</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>von Boehmer</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Zippelius</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Mayer</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Reck</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Atanackovic</surname>
    <given-names>D.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer</article-title>
  <source>Cancer Immunol. Immunother. CII</source>
  <year>2019</year>
  <volume>68</volume>
  <fpage>799</fpage>
  <lpage>812</lpage>
  <pub-id pub-id-type="doi">10.1007/s00262-019-02315-x</pub-id>
  <?supplied-pmid 30770959?>
  <pub-id pub-id-type="pmid">30770959</pub-id>
 </element-citation>
</ref>
